Users on an oral steroid cycle may experience a sudden increase in body weight and muscular development, insomnia, irritability, aggressive combative behavior, puffy face, severe acne, bad breath, a yellowing of the eyes and skin, premature hair loss, hyperactivity, and exaggerated mood swings that include uncontrollable outbursts of anger. Males may also experience testicular shrinkage and can develop female breast tissue on the pectoral muscles. Females may also experience a deeper voice and decreased breast size. Continued use can result in life-threatening situations involving the liver, cardiovascular system, and brain.
The determination of oral turinabol (4-chloro-17 alpha-methyl-17 beta-hydroxy-1,4-androstadien-3-one)  in the 'free' fraction of human urine samples by gas chromatography and capillary column gas chromatography/mass spectrometry was studied. After administration to man, three major metabolites are formed whose structures were identified as 6 beta-hydroxy-turinabol , 6 beta, 12-dihydroxy-turinabol , and 6 beta, 16-dihydroxy-turinabol , respectively. In much smaller quantities at least another three metabolites are excreted, one of which could be identified as 17 epi-turinabol . No measurable amounts of 1 itself were detected in any of the urine samples investigated. The rate of metabolism and urinary excretion is reasonably fast. The total amount of recovered material, in the form of the three main metabolites, is on the order of 15%. Clean-up procedures and chromatographic conditions are presented in detail.